NEW YORK, Jan. 24, 2016 -- Pomerantz LLP announces that a class action lawsuit has been filed against SunEdison, Inc. (“SunEdison” or the “Company”)(NYSE:SUNE) and certain of its officers. The class action, filed in United States District Court, Eastern District of Missouri, Eastern Division, and docketed under 15-cv-01809, is on behalf of a class consisting of all persons or entities who purchased SunEdison securities between June 16, 2015 and October 6, 2015 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
If you are a shareholder who purchased SunEdison securities during the Class Period, you have until February 1, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
SunEdison is a diversified developer of wind and solar energy projects, having developed over 1,300 solar and wind projects in 20 countries. Defendants misled investors by creating the picture that the Company had the financial wherewithal to sustain continued growth. However, as the Company continued its acquisition binge, it was revealed that the Company’s financial viability was materially overstated.
The price of SunEdison stock began its decline on July 20, 2015, after the Company had announced yet another acquisition it did not have the cash to support. On October 5, 2015, Company could no longer hide its prior misstatements when it revealed that it was laying off a 15 percent of its workforce.
Once the truth was revealed, SunEdison's stock dropped to $8.69 from a high of $30.96 at the start of the class period on June 16, 2015, a 72 percent price fall.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]


Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Italy Fines Apple €98.6 Million Over App Store Dominance
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 



